With Novo Nordisk’s Wegovy already in the market, Eli Lilly is stepping up its game with a patient-friendly pen device, intensifying the race for India's booming obesity drug market.

The Tempo pen is currently compatible with three of Lilly's insulin products, including Humalog and Lyumjev, both insulin lispro-based, and insulin glargine brand Basaglar.

The United States insulin pen market size was valued at USD 4.2 billion in 2024 and is projected to hit around USD 8.1 billion by 2033, growing at a CAGR of 6.9% during the forecast period 2025 to ...

Novo Nordisk is banking on its pen-filled device and insulin leadership in India to gain a strong market share despite ...

US pharma giant Eli Lilly has secured Indian regulatory approval to market Mounjaro pen, its widely used diabetes and weight-loss drug. Available in six dosages, Mounjaro helps manage type 2 ...

Get the latest Eli Lilly and Company (LLY) stock news and headlines to help you in your trading and investing decisions.

Eli Lillys Mounjaro KwikPen gains approval in India, targeting diabetes and obesity with its dual-action formula for weight management.

India’s drug regulator has approved Eli Lilly and Company’s diabetes and obesity drug Mounjaro in a KwikPen presentation, the pharmaceutical giant an ...

Novo Nordisk has made its smart insulin pens available in the UK, giving people treated within the NHS for diabetes access to devices that can monitor and record dosing information for the first ...

While Eli Lilly gained an early mover advantage with Mounjaro’s March 2025 launch, Novo Nordisk is counting on its pen-device format and insulin market leadership to help it close the gap, its ...

Eli Lilly said on Thursday that India's drug regulator had approved the launch of pre-filled injector pens of its blockbuster weight-loss drug, Mounjaro, giving it more options to compete with ...